Barrington Research Maintains SurModics Outperform

Loading...
Loading...
Barrington Research maintains its Outperform rating and $18 price target on SurModics
SRDX
in a research report out today on the heels of 1Q 2012 revenues for SurModics that fell just short of 1Q 2011 revenues. In the report, Barrington Research writes, "We are maintaining our OUTPERFORM rating and $18 target as we believe SRDX has an opportunity to buy back close to 40% of the market cap and create an appropriate capital base from which it can generate sustainable return that can provide an expectation for growth." Shares of SurModics are currently trading at $13.85, down 2.88% from Friday's market close.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst Ratings
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...